Statins Enhance the Molecular Response in Chronic Myeloid Leukemia when Combined with Tyrosine Kinase Inhibitors

Statins Enhance the Molecular Response in Chronic Myeloid Leukemia when Combined with Tyrosine Kinase Inhibitors

Previous studies have suggested that statins can be repurposed for cancer treatment. However, the therapeutic efficacy of statins in chronic myeloid leukemia (CML) has not yet been demonstrated. In this study, we retrospectively evaluated the outcomes of 408 CML patients who underwent imatinib thera...

Full description

Saved in:
Bibliographic Details
Main Authors: Hyeok-Jae Jang, Young-Min Woo, Kazuhito Naka, Jong-Ho Park, Ho-Jae Han, Hee-Jin Kim, Sun-Hee Kim, Jae-Sook Ahn, Taehyung Kim, Shinya Kimura, Sarah Zarabi, Jeffrey H. Lipton, Mark D. Minden, Chul-Won Jung, Hyeoung-Joon Kim, Jong-Won Kim, Dennis Dong Hwan Kim
Format: article
Language:EN
Published: MDPI AG 2021
Subjects:
CML
drug resistance
statin
tyrosine kinase inhibitor
combination therapy
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Online Access:https://doaj.org/article/8322a5e3f83e40388263140905c6e5f5
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items